Skinbiotherap. Regulatory News (SBTX)

SkinBioTherapeutics plc

Exercise of Warrant

Manchester, UK - 15 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that it has received notification for the exercise of warrant over 890,314 ordinary shares in the Company at an exercise price of 9 pence per share providing the Company with proceeds of £80,128.26 ("Warrant Exercise").

Application will be made to the London Stock Exchange to admit the 890,314 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 19 March 2021 ("Admission"). The new ordinary shares will rank pari passu with the existing ordinary shares.

For the purpose of the Disclosure and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 156,780,236 ordinary shares of 1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

-Ends-

 For more information, please contact: